Eisai: Aim To Overcome Patent Loss Through Organic Growth
Eisai Co. Ltd. (4523.TO) said Thursday it aims to overcome an
expected drop in revenue from the expiry of the U.S. patent of its
best-selling prescription drug by launching new products and
expanding existing operations.
Company president Haruo Naito said the expiry in November this
year of the U.S. patent on its Aricept Alzheimer's drug is expected
to cause a Y105 billion decline in sales by the fiscal year ending
But Naito said his company can offset the drop with a Y65
billion increase in revenue in the U.S. through introducing new
drugs and boosting sales of existing drugs, as well as a Y20
billion growth in domestic sales and another Y20 billion boost from
its growth in China by March 2013.
Among major products planned for launch in the new fiscal year
from April, Eisai expects its breast cancer drug Eribulin to
generate peak-level annual sales of $1 billion.
Eisai also expects its sepsis treatment Eritoran to bring in $1
billion in peak annual sales.
As for its business in China, the company aims in two years to
double its forecasted sales of Y20 billion for the next fiscal year
ending March 2011, Naito said.
Eisai also aims to lift its return on equity to around 15% in
the year to March 2012, from 9.7% forecast for the current fiscal
year, and earnings per share to Y228 from the current Y141.4 over
the same period, Naito said.
-By Kazuhiro Shimamura, Dow Jones Newswires; 813-6269-2790;